Journal
CELL METABOLISM
Volume 32, Issue 5, Pages 704-709Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2020.09.007
Keywords
-
Categories
Funding
- Lustgarten Foundation
- David C. Copley Foundation
- Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant [SU2C-AACR-DT-20-16]
- National Cancer Institute [P30-CA023100]
- SU2C-Lustgarten Foundation Pancreatic Cancer Interception Dream Team grant [SU2C-AACR-DT-25-17]
Ask authors/readers for more resources
SARS-CoV-2 pneumonitis can quickly strike to incapacitate the lung, leading to severe disease and sometimes death. In this perspective, we suggest that vitamin D deficiency and the failure to activate the vitamin D receptor (VDR) can aggravate this respiratory syndrome by igniting a wounding response in stellate cells of the lung. The FDA-approved injectable vitamin D analog, paricalcitol, suppresses stellate cell-derived murine hepatic and pancreatic pro-inflammatory and pro-fibrotic changes. Therefore, we suggest a possible parallel program in the pulmonary stellate cells of COVID-19 patients and propose repurposing paricalcitol infusion therapy to restrain the COVID-19 cytokine storm. This proposed therapy could prove important to people of color who have higher COVID-19 mortality rates and lower vitamin D levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available